Lineage Cell Therapeutics, Inc. Deferred Revenue
Lineage Cell Therapeutics, Inc. (LCTX) had Deferred Revenue of $1.68 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-08-06
- 2026-06-30: Deferred Revenue, Current $1.68M.
- 2026-03-31: Deferred Revenue, Current $1.72M.
- 2025-12-31: Deferred Revenue, Current $3.33M.
- 2025-09-30: Deferred Revenue, Current $3.77M.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.68M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.72M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $3.33M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $3.77M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $5.26M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $6.93M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $7.39M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $8.25M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $9.14M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $10.11M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $10.81M 10-K · filed 2025-03-10 | |
| 2023-06-30 | $10.38M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $11.01M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $9.42M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $12.36M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $15.79M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $14.88M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $18.12M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $975.00K 10-Q · filed 2021-11-10 | |
| 2021-03-31 | $101.00K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $193.00K 10-K · filed 2022-03-10 | |
| 2020-03-31 | $200.00K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $45.00K 10-K · filed 2021-03-11 | |
| 2019-09-30 | $182.00K 10-Q · filed 2019-11-12 | |
| 2018-12-31 | $42.00K 10-K · filed 2020-03-12 | |
| 2018-09-30 | $43.00K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $103.00K 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $202.00K 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $309.00K 10-Q · filed 2018-11-08 | |
| 2017-09-30 | $513.00K 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $621.00K 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $679.00K 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $572.00K 10-Q · filed 2017-11-09 | |
| 2016-09-30 | $537.00K 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $627.00K 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $609.00K 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $439.00K 10-K · filed 2017-03-16 | |
| 2015-09-30 | $278.00K 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $360.00K 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $178.55K 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $208.00K 10-K · filed 2016-03-15 | $208.36K 10-K · filed 2015-03-11 |
| 2014-09-30 | $177.57K 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $270.35K 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $177.59K 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $235.28K 10-K · filed 2015-03-11 | |
| 2013-09-30 | $349.85K 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $462.77K 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $394.34K 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $400.87K 10-K · filed 2014-03-17 | |
| 2012-09-30 | $354.70K 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $476.22K 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $201.54K 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $203.77K 10-K · filed 2013-03-18 | |
| 2011-09-30 | $199.86K 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $220.87K 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $288.31K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |